Alzheimers disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimers disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimers disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy
Conditions
Interventions
Amyloid PET: Given the flutemetamol (2mL) intravenously
FDG-PET:Given the FDG scanR (2mL) intravenously
Sponsors
Itoh Yoshiaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy control 1. Ages 20 and over 2. Written informed consent Patient 1. Diagnosed as neurogenerative disease related to tau protain (Alzheimer's disease, Dementia with Lewy Bodies, Frontotemporal lobar degeneration, Parkinson's syndrome) by clinical symptom, Neurological findings, MRI and cognitive function test. 2. Written informed consent
Exclusion criteria
Exclusion criteria: Healthy control 1. A person who has brain disease (Parkinson's disease, dementia related disease, etc.) 2. A person who has serious disease complications or who has a history of these and who is considered as inappropriate by researcher. 3. Pregnant, unwilling to practice contraception during the study, or lactating female. 4. Participated in nuclear medicine examination within 6 months. 5. Claustrophobia 6. Judged inappropriate as subject by investigator. Patient 1. A person who is complicated by brain disease other than the disease concerned (including an obvious history of cerebral infarction) and taking a drug that effects on the central nervous system 2. A person who has serious disease complications or has a history of these and is judged to be unsuitable as a subject of this research by a doctor who is a researcher etc. 3. Pregnant, unwilling to practice contraception during the study, or lactating female. 4. Participated in nuclear medicine examination within 6 months. 5. Claustrophobia 6. Judged inappropriate as subject by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Differences in flutemetamol uptake in each patients 2. Differences in FDG uptake between patients and healthy controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between brain distribution of flutemetamol and clinical symptoms, neuropsychological examination, cerebrospinal fluid test and MRI | — |
Contacts
Public ContactYoshiaki Itoh
Osaka Metropolitan Univesity Hospital
Outcome results
None listed